Hemogenyx Pharmaceuticals Revenue vs. Total Debt

HEMO Stock   343.40  20.90  6.48%   
Based on Hemogenyx Pharmaceuticals' profitability indicators, Hemogenyx Pharmaceuticals PLC may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Hemogenyx Pharmaceuticals' ability to earn profits and add value for shareholders.
 
Total Revenue  
First Reported
2010-12-31
Previous Quarter
0.0
Current Value
0.0
Quarterly Volatility
3.5 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
For Hemogenyx Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Hemogenyx Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Hemogenyx Pharmaceuticals PLC utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Hemogenyx Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Hemogenyx Pharmaceuticals PLC over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis.
Please note, there is a significant difference between Hemogenyx Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hemogenyx Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hemogenyx Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Hemogenyx Pharmaceuticals Total Debt vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Hemogenyx Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Hemogenyx Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Hemogenyx Pharmaceuticals PLC is currently under evaluation in revenue category among its peers. It is rated as one of the top companies in total debt category among its peers . At this time, Hemogenyx Pharmaceuticals' Total Revenue is comparatively stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Hemogenyx Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Hemogenyx Revenue vs. Competition

Hemogenyx Pharmaceuticals PLC is currently under evaluation in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 37.91 Billion. Hemogenyx Pharmaceuticals adds roughly 0.0 in revenue claiming only tiny portion of equities under Health Care industry.

Hemogenyx Total Debt vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Hemogenyx Pharmaceuticals

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
null
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Hemogenyx Pharmaceuticals

Total Debt

 = 

Bonds

+

Notes

 = 
2.95 M
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Hemogenyx Total Debt vs Competition

Hemogenyx Pharmaceuticals PLC is rated as one of the top companies in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 10.6 Billion. Hemogenyx Pharmaceuticals adds roughly 2.95 Million in total debt claiming only tiny portion of equities under Health Care industry.
Total debt  Capitalization  Valuation  Revenue  Workforce

Hemogenyx Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Hemogenyx Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Hemogenyx Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Hemogenyx Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Hemogenyx Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income1.1 M1.1 M
Operating Income-6.5 M-6.1 M
Income Before Tax-6.7 M-6.4 M
Net Loss-6.7 M-6.4 M
Total Other Income Expense Net-230.6 K-242.2 K
Income Tax Expense-5.8 K-5.5 K
Interest Income85.3 K89.6 K
Net Loss-6.7 M-6.4 M
Net Loss-4.6 M-4.4 M
Net Interest Income-230.6 K-242.2 K
Change To Netincome725.5 K845.2 K

Hemogenyx Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Hemogenyx Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Hemogenyx Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Hemogenyx Pharmaceuticals' important profitability drivers and their relationship over time.

Use Hemogenyx Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Hemogenyx Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Hemogenyx Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Hemogenyx Pharmaceuticals Pair Trading

Hemogenyx Pharmaceuticals PLC Pair Trading Analysis

The ability to find closely correlated positions to Hemogenyx Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Hemogenyx Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Hemogenyx Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Hemogenyx Pharmaceuticals PLC to buy it.
The correlation of Hemogenyx Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Hemogenyx Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Hemogenyx Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Hemogenyx Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Hemogenyx Pharmaceuticals position

In addition to having Hemogenyx Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Large Growth Funds Thematic Idea Now

Large Growth Funds
Large Growth Funds Theme
Funds or Etfs that invest in stocks of large-sized companies with above-average risk and growth rate. The Large Growth Funds theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Growth Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Hemogenyx Stock Analysis

When running Hemogenyx Pharmaceuticals' price analysis, check to measure Hemogenyx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemogenyx Pharmaceuticals is operating at the current time. Most of Hemogenyx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hemogenyx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemogenyx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hemogenyx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.